ALLYRNA

Hong Kong, Hong Kong · Founded 2025 · Privately Held (backing)

Developer of RNA-based biopharmaceutical technologies intended to accelerate therapeutic innovation in precision medicine. ALLYRNA is based in Hong Kong, Hong Kong and was founded in 2025. It has raised $10 million.

Last price · $/share
—
Implied valuation
—
Total raised
$10.0M
Last round
—
Valuation — not yet established

No valuation for ALLYRNA is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($10.0M) and the funding record below are the closest available signals.

Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of ALLYRNA with a free account
  • ·Watch ALLYRNA: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

ALLYRNA funding history

No rounds on record

No funding rounds for ALLYRNA are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

How ALLYRNA's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For ALLYRNA, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →

Frequently asked about ALLYRNA

How much has ALLYRNA raised?
ALLYRNA has raised $10.0M in total funding across its recorded rounds.